Abstract:Introduction Different autoimmune conditions have been described in human immunodeficiency virus (HIV) patients on antiretroviral therapy (ART), but muscle-specific kinase (MuSK) myasthenia gravis (MG) coexisting with HIV is rare. We report a case of a Chinese patient with an asymptomatic HIV infection who presented with newly-onset MuSK MG and was managed successfully with the acetylcholinesterase inhibitor pyridostigmine. Case report A 71-year-old Chinese male from Zhejiang province had an established HIV infection and was on ART since 2014. He presented to the outpatient clinic stating that for the last 5 days he had been experiencing double ptosis, weakness in the neck, and difficulty to hold up his head, which were all worsening in the evening. He had been on ART consisting of Zidovudine 300 mg BID, Lamivudine 300 mg QD, and Nevirapine 200 mg BID. Although he was diagnosed and started on ART in 2014, he was subsequently followed up and had undetected viral loads with CD4 counts of 100–150 cells/μL in 2017. So, the highly active antiretroviral therapy (HAART) was changed in October 2017, and subsequently consisted of Tenofovir 300 mg QD, Lamivudine 300 mg QD, and Efavirenz 600 mg QD. His CD4 counts had increased to 183 cells/μL by April 2018. He had hypertension since 1999 and was treated with L-amlodipine and irbesartan. He had type 2 diabetes since 1999 and was treated with insulin aspartate and insulin glargine. Review of other systems was negative. On examination, he had bilateral ptosis with serious left ptosis covering the inferior margin of the pupil, and cervical extensors were at 4-strength. Fatigue tests of bilateral palpebral muscles were positive and the bilateral tendon reflex was positive. Other cranial nerves were intact. Motor, sensory, coordination, and other deep-tendon reflexes were normal. Routine blood tests, creatinine kinase, anti-nuclear antibody, anti-neutrophil cytoplasmic antibodies, rheumatoid factor, thyroid function, and anti-thyroid antibodies were normal. Total IgG titers were mildly elevated (1878 mg/dL, reference range 800–1800 mg/dL, and IgA, IgM, C3, and C4 were within normal limits. Hepatitis C antibodies were negative. Brain magnetic resonance imaging did not show any neurological abnormalities and computerized tomographic scanning of the chest did not show any significant enlargement of the thymus. His acetylcholine receptor (AChR) antibodies were negative, while MuSK antibodies were 12.00 U/mL (MuSK autoantibody titer along with cutoff 0.40 U/mL). Repetitive nerve stimulation tests (3 Hz) showed normal findings. He received oral pyridostigmine therapy (360 mg daily) soon after diagnosis of MuSK antibody-positive MG in September 2018, which resulted in resolution of ptosis and bulbar symptoms and incomplete improvement of neck weakness. However, he experienced double ptosis and weakness in the neck again when pyridostigmine was reduced to a daily dosage of 180 mg in February 2019. So, the dose of oral pyridostigmine was reduced slowly and he responded to oral pyridostigmine therapy with daily dosages of 240–180 mg from February to June 2019. By July 2019, all his symptoms had improved dramatically and pyridostigmine was stopped. He experienced continuous improvement of CD4+ T cells (202 cells/μL) with undetectable HIV viral loads. Up to January 2020, none of his symptoms reappeared. Discussion MG is an autoimmune disease that is associated with antibodies affecting the postsynaptic membrane at the neuromuscular junction.1,2 80% of MG patients have detectable antibodies against AChR, while a minority has antibodies against MuSK and lipoprotein-receptor-related protein 4.2 Overall, 1%–10% of the MG patients have serum MuSK antibodies.1 MuSK is a protein expressed in the postsynaptic muscle membrane and linked to AChR to maintain AChR function. MuSK MG is estimated to have a prevalence of 2.9 per million people in Europe.3 In China, MuSK MG is more common in the north.4 Although MG is one of the best-characterized and understood autoimmune disorders, comorbidity of HIV and MG is rare and mostly reported in incidental case reports.5 Hung et al.6 previously summarized the common characteristics of these comorbid HIV and MG patients: (1) MG develops in the early stage of HIV infection when the immune system is relatively intact; (2) the clinical course of MG appears to be benign and most patients show improvements along with advancing immunodeficiency; (3) serum anti-AChR antibodies are absent or show low titers; (4) there is little association of thymus hyperplasia as opposed to patients with AChR-Ab-positive myasthenia. Clinical features of MuSK MG resemble AChR-Ab MG, but MuSK MG patients show predominant involvement of cranial and bulbar muscles with increased incidence of ptosis, diplopia, and dysarthria, prominent with neck and respiratory muscle involvement and are less responsive to acetylcholinesterase inhibitors.7 MuSK MG may have a different cause and pathologic mechanism compared with AChR-Ab-positive MG.1,2 Comorbidity of HIV and MuSK MG is very rare, with only five cases previously reported, and very little is known about this association.8–12 These cases are summarized in Table 1. Among them, two are African Americans, while the other three are African, Japanese, and someone from Thailand. In our case, the MuSK MG patient with HIV infection came from Zhejiang province, in the south of China. One case report showed no MG relapse in an HIV-infected patient who was successfully treated with efavirenz-containing therapy.13 However, our patient, who was on Efavirenz-containing HAART, was just being diagnosed with MuSK MG. All these five case reports have described MuSK MG in HIV as part of immune reconstitution after antiretroviral treatment, in which MG was manifested as CD4 counts improved after HAART.8–12 A similar pattern was seen in the presentation of our patient, in whom the improvement of CD4 counts with changes of antiretroviral drug led to presentation of the symptoms. The following improvement of MG was accompanied with increasing CD4+ T cell counts. A consistent finding in patients with MuSK MG is that they have a much lower frequency of thymic pathology than patients with AChR-Ab-positive MG.14 This finding is consistent in all the aforementioned cases summarized in Table 1, including our patient. A possible explanation might be the normalization of immune regulation and the remount of CD4+ suppressor-inducer or regulatory T cells.Table 1: Comparison of case reports on MuSK myasthenia gravis and HIV.The management of patients with both HIV and MuSK MG is challenging. Immunosuppressants and immunomodulators have been used for the treatment of MuSK MG in HIV patient based on case reports, and was not entirely without risk.8–12 All of the five reported cases listed in Table 1 had similar findings along with positive MuSK antibodies and were subsequently treated with immunomodulators like cyclosporine, intravenous immunoglobulin, azathioprine, rituximab, and plasma exchange. Different from other cases of MG with worsening symptoms, our patient was managed with the acetylcholinesterase inhibitor pyridostigmine, which improved his symptoms successfully. Therefore, due to the lack of studies on treatment of MuSK MG in HIV patients, the use of steroids and immunomodulators should be cautiously evaluated in each patient. In conclusion, we propose that the relationship between HIV infection and MuSK MG is not just a coincidence. The Chinese old man with an established HIV infection developed new-onset MuSK MG when he was on Efavirenz-containing HAART. The improvement of MG was actually accompanied with increasing CD4+ T cell counts after changes of prescribed antiretroviral drugs and MG was successfully managed with the acetylcholinesterase inhibitor pyridostigmine. Further research is needed to identify the underlying immuno-pathogenesis and to prevent and treat MuSK MG in HIV patients.

Anti-MuSK Antibody-positive Myasthenia Gravis Successfully Treated with Outpatient Periodic Weekly Blood Purification Therapy

MuSK Myasthenia Gravis in an HIV-infected Chinese Old Man Successfully Treated with Pyridostigmine

Clinical application of blood purification in polymyositis/dermatomyositis

Myasthenia gravis with antibodies to MuSK: an update

Pembrolizumab-induced Myopathy with Anti-striated Muscle Antibodies Successfully Treated by Plasma Exchange

Case report: Rapid clinical improvement in acute exacerbation of MuSK-MG with efgartigimod

Effects of Plasma Exchange Combined with Immunoglobulin Therapy on Consciousness, Immune Function, and Prognosis in Patients with Myasthenia Gravis Crisis: A Prospective Randomized Test

Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease

Agonist antibody to MuSK protects mice from MuSK myasthenia gravis

Efficacy and Safety of Low-Dose Rituximab in Anti-MuSK Myasthenia Gravis Patients: A Retrospective Study

A clinical perspective on muscle specific kinase antibody positive myasthenia gravis

Lymphoplasma Exchange Improves Myasthenia Gravis Exacerbations: A Retrospective Study in a Chinese Center

Therapeutic Plasma Exchange and Supratherapeutic Levels of Unfractionated Heparin in the Management of Critically Ill Patient with Myasthenia Gravis: A Case Report

Three AChR-Ab and MuSK-Ab double-seropositive myasthenia gravis patients and review of literature

Immunoadsorption therapy in late-onset myasthenia gravis

A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression

MuSK-Associated Myasthenia Gravis: Clinical Features and Management

Application of lymphoplasmapheresis in the treatment of severe myasthenia gravis

Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation

Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models

Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: A prospective cohort study